Company intelligence / Profile preview

BioAces

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

BioAces develops and markets real-time, multimodal live cell imaging, flow cytometry, and high-content imaging instruments aimed at bioprocess monitoring and cell analysis in biologics process development (e.g. vaccines, ADC, mAbs, CGT). Its technology enhances process efficiency and product quality monitoring for biopharma manufacturing. The company has successfully commercialized at least two products and has additional pipeline technologies in development[1][2][4].

Modalities: BiologicsMonoclonal antibodyAntibody-drug conjugateCell therapyVaccine
Industry: Pathology

Partnerships

Duoning (expanded cell analysis technology portfolio via partnership)

Beyond the preview

Go deeper on BioAces.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioAces.

Explore the full profile